In this episode, Ipsos' Alyssa Rowan sits down with David Bateson and Professor Fiona Gilbert to explore cutting-edge advancements in oncology. We dive into how artificial intelligence and innovative screening methods are reshaping early cancer detection and improving patient outcomes.

We also discuss the importance of proactive risk stratification and predicting treatment responses, as well as the challenges of implementing these ground breaking technologies and the necessary steps to ensure they are accessible and equitable for all.

On World Obesity Day: we’ve built the on-ramp to anti-obesity medications - but is what comes next an off-ramp or a cliff?

Anna Meadows is joined by Professor Naveed Sattar in the latest episode of The Big Picture Podcast to explore what happens when treatment stops and whether the behavioural support around GLP-1s is strong enough to make weight loss durable. From reduced ‘food noise’ and the window for behaviour change, to the realities of living in an obesogenic environment, this conversation explores what it really takes to make weight loss last and why rapid regain matters for patients and health systems alike.

Helen Bennis, Senior Director at Ipsos chats with Dr Stephanie Anne Baker, Reader at City University of London whose research focuses on how rumours, false, and misleading information travels online with a particular focus on health and wellness, and, Dr Camilla Stokholm, GP and author of ‘What your doctor eats’.

In this second of the two part series they discuss:

- What harm inaccurate, unethical and unregulated health information can cause

- How to identity trusted sources (and those masquerading as trusted sources)

- Why everyone should be evaluating their information diet (and how to do that).

Helen Bennis, Senior Director at Ipsos, chats with Dr Stephanie Anne Baker, whose research focuses on how rumours, false, and misleading information travels online with a particular focus on health and wellness, and, Dr Camilla Stokholm, GP and author of ‘What your doctor eats’.

In the first of two parts they discuss:

• The profound benefit accurate and well-intentioned online health information can have on peoples’ lives, using Dr Camilla Stockholm’s personal experience as an ‘accidental influencer’
• The reasons why we have seen a proliferation of online mis / dis information in recent years
• The strategies employed to gain trust online and how this has changed over time

Obesity care in the US is in the midst of a true transformation — one that’s redefining science, access, and the patient experience.

In the latest episode of Obesity: The Big Picture Podcast, Jackie Ilacqua, President of Syndicated Healthcare Research at Ipsos, is joined by two of the leading voices in obesity and metabolic research — Dr. Donna Ryan and Professor David Allison — to explore how innovation, access, and trust are redefining what effective obesity care looks like today.

From breakthrough therapies and expanding Medicare coverage to the emerging understanding of “food noise” and the challenge of public trust, this episode unpacks the forces driving this new era of care.

But as access to GLP-1 therapies grows, important questions remain: Who’s being left out, and why? How do we ensure that innovation doesn’t widen existing gaps in care and equity?

Tune in to 'Spotlight on the US Obesity Care Revolution' to hear how science, policy, and people are converging to shape the next chapter of obesity treatment in America.

Real world evidence is changing the healthcare landscape, but what does it mean in practicality for chronic diseases like obesity?

In this episode of Obesity: The Big Picture podcast, host Ramota Alaran, Associate Director of Real-World Evidence at Ipsos, sits down with independent consultant Madhu Kubra (formerly Global Director at Otsuka and GSK) to unpack how real-world evidence (RWE) is transforming obesity research, care, and policy.

From integrated evidence planning to the utilisation of the patient voice in RWE studies, this episodes tackles the types of real world data that can be used to address the obesity crisis and what regulators need to be considering.

Want to learn more? Register today to join us at our RWE event, 30 October: https://www.ipsos.com/en-uk/amplifying-patient-voice-real-world-evidence

What happens when breakthrough drugs collide with outdated systems of access?

In this episode, Ipsos' Kiran Khepar and Neil Grubert, Global Market Access Consultant, explore the friction between innovation and access, and what it means for the future of healthcare systems.

GLP-1 therapies are redefining what’s possible in obesity treatment, but reimbursement pathways haven’t caught up. From out-of-pocket models to public payer resistance, we’re unpacking how market dynamics are shaping who really gets treated and who’s left behind.

Obesity isn't just a number on a scale – it's a complex, chronic condition that demands long-term, system-wide change.

In this episode, Ipsos' Melissa Moodley and Anthony Cunliffe, Macmillan National Lead Medical Adviser, dive into what the UK Government’s 10-Year Plan for Health means for primary care, how we can reshape obesity care at the frontline, and what it takes to build a health service fit for the future.

From early intervention and stigma reduction to team-based models and real-world evidence, this episode brings the policy to life through practical insights.

Listen to Ipsos' Brooke Ramsdale and Sarah Le Brocq, Director, All About Obesity, discuss the lived realities of people with obesity, offering real-world insights into how they navigate the evolving treatment landscape. They explore the everyday challenges encounter in accessing comprehensive care and confronting societal perceptions, alongside aspirations for a future where obesity is understood and treated with empathy, equity, and genuine innovation.

Listen to Thomas Fife-Schaw and Nick Gabery Adams, former VP of Corporate Brand at Novo Nordisk, discuss how GLP-1 medications like Ozempic and Wegovy are changing the pharmaceutical landscape. From reshaping corporate reputation, to boosting investor confidence, discover how these drugs are rewriting the rules for pharma brands.